Optical pooled screening service using ARADIA™ to link CRISPR and other perturbations to microscopy-based single-cell phenotypes.
Biocartesian offers optical pooled screening for cell biology using its proprietary ARADIA™ (Amplified Random Access DNA Imaging Assay) technology, which reads targeted DNA sequences in situ to connect pooled perturbations to image-rich single-cell phenotypes. The service supports genome-wide or targeted CRISPR screens, CAR variant screening, UTR libraries, drug response studies, and live-cell readouts. Teams can use Biocartesian for full-service screen execution or ARADIA™ readout and analysis only. Biocartesian is a product of Biocartesian.